Clinical Trial Update: Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial of the Wee1 inhibitor AZD1775 (adavosertib) with combination chemotherapy for relapsed or refractory acute myeloid leukemia in children, adolesc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZD1775 (Adavosertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: CNS 2a, CNS 2b | Phase 1 | Status: WITHDRAWN